
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
GRLSbn | Madrid | EUR | Delayed | |
GRLS | Derived | EUR | Real-time | |
GRLS | Madrid | EUR | Delayed | |
GRFPe | BATS Europe | EUR | Delayed | |
GRFe | BATS Europe | EUR | Delayed | |
GIKLY | OTC Markets | USD | Delayed | |
GRFS | NASDAQ | USD | Real-time | |
0RDU | London | EUR | Real-time | |
0RDV | London | EUR | Real-time | |
GRFPN | Mexico | MXN | Delayed | |
GRLS | Vienna | EUR | Real-time |
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada and internationally. The Biopharma segment provides plasma derivatives products, including Gamunex/Gamunex-C Immune Globulin Injection, Flebogamma Immune Globulin Intravenous, Xembify Immune Globulin Subcutaneous solution, HyperRAB Rabies Immune Globulin, Prolastin/Prolastin-C/Prolastin-C Liquid/Prolasplan/Prolastina/Pulmolast/Lynspad Alpha 1-Proteinase Inhibitor, Fanhdi and Alphanate, Antihemophilic Factor/von Willebrand factor Complex, Koate-DVI Antihemophilic Factor, Albutein/Albutein Flexbag/ Human Albumin Grifols/Plasbumin Albumin, and Vistaseal/Veraseal; and Tavlesse, a non-plasma derivative medicinal product. The Diagnostic segment offers transfusion medicine, which includes Procleix Panther systems/Procleix Panther with Automation Ready technology, Automated NAT blood screening systems, assays, software, WADiana/Erytra/Erytra Eflexys analyzers, BLOODchip ID/IDCore/IDHPA/IDRHD/IDCORE/BIDS, and antigens; and clinical and diagnostics products, such as Promonitor and Alpha1D. The Bio Supplies segment provides human biological materials for life sciences research and the development and manufacturing of pharmaceutical and diagnostic products. The Others segment offers healthcare solutions, which provides services and manufactures products, including parenteral solutions, robotics, and software used by hospitals, blood banks, plasma collection centers and other healthcare systems. The company’s products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. Grifols, S.A. has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products, and with GIANT and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Name | Age | Since | Title |
---|---|---|---|
Inigo Sánchez-Asiaín Mardones | 59 | 2015 | Independent Director |
Montserrat Muñoz Abellana | 55 | - | Independent Director |
Carina Szpilka Lázaro | 55 | 2015 | Lead Independent Director |
Enriqueta Felip Font | 59 | 2019 | Independent Director |
Juan Ignacio Twose Roura | 77 | 1973 | Member of the Advisory Committee |
James Costos | 60 | 2020 | Independent Director |
Victor Grifols Roura | 73 | 1985 | Chairperson of Honor |
Thomas H. Glanzmann | 65 | 2006 | CEO & Executive Chairman |
Tomas Daga Gelabert | 67 | 2000 | Vice Secretary & Independent External Director |
Víctor Grifols Deu | 46 | 2016 | COO & Director |
Raimon Grifols Roura | 59 | 2001 | Chief Corporate Officer & Vice-Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review